Last update 20 Mar 2025

Anti-CD19 antibody-conjugated doxorubicin liposomal nanoparticle (Nanovalent Pharmaceuticals)

Overview

Basic Info

Drug Type
Antibody drug conjugate (ADC), Liposomal Drug
Synonyms
DoxantiCD19
Target
CD19 x Top II
Action
inhibitors
Mechanism
CD19 inhibitors(B-lymphocyte antigen CD19 inhibitors), Top II inhibitors(Topoisomerase II inhibitors)
Therapeutic Areas
NeoplasmsImmune System DiseasesHemic and Lymphatic Diseases
Active Indication
Acute Lymphoblastic LeukemiaAcute Myeloid Leukemia
Inactive Indication-
Originator Organization
NanoValent Pharmaceuticals, Inc.NanoValent Pharmaceuticals, Inc.
Active Organization
NanoValent Pharmaceuticals, Inc.NanoValent Pharmaceuticals, Inc.
Inactive Organization-
Drug Highest PhasePreclinical
First Approval Date-
Regulation-

Structure/Sequence

Molecular FormulaC27H29NO11
InChIKeyAOJJSUZBOXZQNB-TZSSRYMLSA-N
CAS Registry23214-92-8
Boost your research with our ADC technology data.
login
or
view full example data
Boost your research with our ADC technology data.

Related

100 Clinical Results associated with Anti-CD19 antibody-conjugated doxorubicin liposomal nanoparticle (Nanovalent Pharmaceuticals)
Login to view more data
100 Translational Medicine associated with Anti-CD19 antibody-conjugated doxorubicin liposomal nanoparticle (Nanovalent Pharmaceuticals)
Login to view more data
100 Patents (Medical) associated with Anti-CD19 antibody-conjugated doxorubicin liposomal nanoparticle (Nanovalent Pharmaceuticals)
Login to view more data
100 Deals associated with Anti-CD19 antibody-conjugated doxorubicin liposomal nanoparticle (Nanovalent Pharmaceuticals)
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Acute Lymphoblastic LeukemiaPreclinical
United States
NanoValent Pharmaceuticals, Inc.NanoValent Pharmaceuticals, Inc.
30 Jan 2022
Acute Myeloid LeukemiaPreclinical
United States
NanoValent Pharmaceuticals, Inc.NanoValent Pharmaceuticals, Inc.
-
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
view full example data
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free